COMMUNIQUÉS West-GlobeNewswire

Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
08/10/2026
New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment pace Initial readout timing to be updated by year-end based on demonstrated Q4 enrollment increases Overall [...]
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
08/10/2026
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will [...]
Ritedose Opens Advanced Laboratory and Expands Analytical Capabilities to Accelerate Pharmaceutical Innovation—Positioning the Company as a Preferred Partner for Drug Development and Manufacturing
08/10/2026
Triples laboratory footprint with the $17 million investment. Features new leachables and extractables testing capabilities. Allows for seamless development and manufacturing experience while supporting pharmaceutical [...]
Cronos Group Inc. to Hold 2026 Third Quarter Earnings Conference Call on November 5, 2026
08/10/2026
TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 third quarter earnings conference call on Thursday, November 5, 2026, at 8:30 a.m. [...]
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
08/10/2026
First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration Expands CNSide contracted payer access to approximately 164 million covered lives HOUSTON, Oct. 08, 2026 [...]
Helus Pharma to Host Investor Presentation on October 21, 2026
08/10/2026
NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing [...]
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
08/10/2026
Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA) Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: [...]
NextWave Peptides Builds a Clearer Standard for Research Peptide Information, Documentation, and Fulfillment
08/10/2026
New York, USA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- U.S. Based Research Peptide Company Focuses on Transparent Product Information, Reviewable Documentation, Competitive Pricing, and Direct Customer Support NextWave [...]
Bio Usawa Takes Major Step Toward Building a Self-Sustaining Biotechnology Ecosystem in Africa
08/10/2026
The establishment of Botswana subsidiary strengthens regional capacity and expands access to affordable biologics SAN FRANCISCO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology today announced the launch of [...]
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
08/10/2026
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p= 0.0176 ) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx [...]
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
08/10/2026
October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod [...]
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
08/10/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
Regulated information – inside information: Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and confirms FY guidance range
08/10/2026
Regulated information – inside information Nazareth-De Pinte (Belgium)/Rotterdam (The Netherlands), 8 October 2026 – 7:00 AM CET Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and [...]
Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance
08/10/2026
Revenue and EBITDA margin expectations increased, driven by stronger-than-expected Travel Health sales COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade to the financial [...]
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
07/10/2026
Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin HIGH POINT, N.C., Oct. 07, 2026 (GLOBE NEWSWIRE) -- vTv [...]
Lifecore Biomedical to Participate at Upcoming Industry Conferences
07/10/2026
CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
07/10/2026
WILMINGTON, Del., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the [...]
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
07/10/2026
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“ [...]
Leo International Precision Health AG: Mr. Leo Wang, Disposal
07/10/2026
Leo International Precision Health AG: Mr. Leo Wang, Disposal Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them, 07. Oct 2026 [...]

Pages